Investigational Drug Information for Lysergic Acid Diethylamide
✉ Email this page to a colleague
What is the development status for investigational drug Lysergic Acid Diethylamide?
Lysergic Acid Diethylamide is an investigational drug.
There have been 20 clinical trials for Lysergic Acid Diethylamide.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 2nd 2019.
The most common disease conditions in clinical trials are Cluster Headache, Headache, and Anxiety Disorders. The leading clinical trial sponsors are University Hospital, Basel, Switzerland, Eleusis Therapeutics, and Radboud University Medical Center.
Summary for Lysergic Acid Diethylamide
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 3,145 |
WIPO Patent Applications | 1,920 |
Japanese Patent Applications | 998 |
Clinical Trial Progress | Phase 2 (2019-01-02) |
Vendors | 10 |
Recent Clinical Trials for Lysergic Acid Diethylamide
Title | Sponsor | Phase |
---|---|---|
LSD Occupancy of the Serotonin 2A Receptor in the Human Brain | Rigshospitalet, Denmark | Early Phase 1 |
Lysergic Acid Diethylamide (LSD) in Palliative Care | University Hospital, Zürich | Phase 2 |
Lysergic Acid Diethylamide (LSD) in Palliative Care | University Hospital, Basel, Switzerland | Phase 2 |
Clinical Trial Summary for Lysergic Acid Diethylamide
Top disease conditions for Lysergic Acid Diethylamide
Top clinical trial sponsors for Lysergic Acid Diethylamide
US Patents for Lysergic Acid Diethylamide
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |